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Abstract
Background: Follicle stimulating hormone (FSH) and Anti-Mu ¨llerian hormone (AMH) are utilized to differentiate between
good and poor response to controlled ovarian hyperstimulation. Their respective roles in defining functional ovarian reserve
remain, however, to be elucidated. To better understand those we investigated AMH and FSH per oocyte retrieved (AMHo
and FSHo).
Methodology/Principal Findings: Three-hundred and ninety-six women, undergoing first in vitro fertilization cycles, were
retrospectively evaluated. Women with oocyte yields .75
th percentile for their age group were identified as high
responders. In a series of logistic regression analyses, AMHo and FSHo levels were then evaluated as predictive factors for
pregnancy potential in high responders. Patients presented with a mean age of 38.065.0 years, mean baseline FSH of
11.868.7 mIU/mL and mean AMH of 1.662.1 ng/mL. Those 88 women, who qualified as high responders, showed mean
FSH of 9.766.5 mIU/mL, AMH of 3.163.1 ng/mL and oocyte yields of 15.867.1. Baseline FSH and AMH did not predict
pregnancy in high responders. However, a statistically significant association between FSHo and pregnancy was observed in
high responders, both after univariate regression (p=0.02) and when adjusted for age, percentage of usable embryos, and
number of embryos transferred (p=0.03). Rate of useable embryos also significantly affected pregnancy outcome
independently of FSHo (p=0.01). AMHo was also associated with clinical pregnancy chances in high responders (p=0.03)
and remained significant when adjusted for usable embryos and number of embryos transferred (p=0.04).
Conclusions: AMHo and FSHo are predictive of pregnancy potential in high responders, but likely reflect different
responsibilities in recruitment and maturation of growing follicle cohorts.
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Reproductive senescence is closely associated with the depletion
of the ovarian follicle pool. The decline of functional ovarian
reserve (FOR), i.e. the cohort of small antral follicles, appears to
reflect this aging process [1,2]. Functional ovarian reserve is
strongly correlated with a variety of measurements, including
follicle stimulating hormone (FSH) [3,4], anti-Mu ¨llerian hormone
(AMH) [5,6] and antral counts [7]. Different assessment tools,
though, subtly, represent different components of FOR [8].
AMH has recently attracted most attention in predicting
ovarian response to controlled hyperstimulation [9,10]. FSH, in
contrast, has proven less successful in predicting large oocyte yields
and hyperstimulation risk [10]. AMH levels are, therefore,
increasingly used to individually tailor and adjust gonadotrophin
dosage in assisted reproduction [11,12,13]. Though AMH and
other ovarian function markers have proven helpful to predict
oocyte yield, their significance in the prediction of egg quality and,
consecutively, pregnancy, remains controversial [14,15,16].
AMH is exclusively produced by granulosa cells of small
preantral and early antral follicles [17]. A statistical association
with number of oocytes, therefore, does not surprise. AMH,
however, is no longer produced at more mature follicle stages.
Continuous association with egg/embryo quality, therefore, would
be more surprising. FSH, in contrast, based on animal data,
appears to have influence on follicle maturation from recruitment
until full maturity [18].
In an attempt to better elucidate the association between FSH
and AMH and oocyte/embryo quantity/quality, we decided to
explore mathematical models of FSH and AMH levels per
retrieved oocyte (FSHo and AMHo) as potentially new tools in
improving assessments of functional ovarian reserve. In the
assumption that any potential qualitative aspect of AMH’s (and
potentially also FSH’s) predictive capacity may only become
apparent in the presence of large enough oocyte yields, we
restricted the study cohort to high responders.
Methods
Ethics Statement
Here presented data only involved retrospective review of
medical records. Patients at our center sign at initial consultation
an informed consent, which allows for such reviews if the patient’s
medical record remains confidential and her identity protected.
These conditions were met in this case, allowing for expedited
approval by the Institutional Review Board (IRB).
Participants
Between January 2005 and July 2011, 396 consecutive patients,
who underwent at least one in vitro fertilization cycle at the Center
for Human Reproduction in New York, N.Y, were retrospectively
evaluated. To preclude the introduction of a potential bias on
pregnancy chances, only first fresh treatment cycles, performed at
our center, were considered for analysis. To identify high, normal
and low responders, the dataset was stratified according to female
age into the following groups: #34, 35–37, 38–40, 41–42, and
$43 years, and by oocyte yields. Patients with oocyte yields above
the 75
th percentile of their age group were coded as high
responders. Normal responders had oocyte yields between the 25
th
and the 75
th percentile of their age group and patients with oocyte
yields below the 25
th percentile of their age group were coded as
low responders. We previously investigated FSHo and AMHo in a
similar patient group of 392 infertile women, with over 60 percent
afflicted by diminished ovarian reserve [19]. This study, therefore,
focused on high responders.
Description of Procedures Undertaken
Baseline serum FSH and AMH were measured at cycle day 2 or
3 prior to cycle start. Serum AMH was obtained using the
Diagnostics System Laboratories (DSL) assay by Beckman Coulter
Inc., Brea, CA. The assay for serum AMH involved an
enzymatically amplified two-site immunoassay, DSL-10-14400
active MIS/AMH ELISA. According to the manufacturer’s
manual, the sensitivity of the assay was 0.025 mg/L with intra-
assay variation ,15% [20]. Serum FSH testing was performed in
our clinical endocrine laboratory. All assays were performed on an
AIA-600II (TOSOH Bioscience, Inc, Tokyo, Japan). The
coefficient of variation of the assays, as determined by summation
of semiannual quality control proficiency testing over this entire
period, has been 8.1%.
All women underwent gonadotropin releasing hormone agonist
(GnRh agonist) cyclesincluding stimulation with follicle stimulating
hormone (FSH) and human menopausal gonadotropin (hMG)
[21]. Women with age-specific normal ovarian function (i.e.,
normal age-specific AMH and FSH levels) received long protocol
stimulation, while women with diminished ovarian reserve
received microdose agonist stimulation [3,22]. Ovulation induc-
tion and oocyte retrieval were performed when at least two follicles
reached a diameter of 18 mm. The diagnosis of a clinical
pregnancy was established by the presence of a fetal heartbeat
on vaginal ultrasound.
In order to assess oocyte-specific AMH levels, the number of
oocytes retrieved was divided by AMH (AMHo). In our prior
manuscript, AMHo was calculated inversely (i.e., AMH divided by
oocyte number). This calculation, however, produced very small
numbers. We, therefore, decided to adapt this calculation. Oocyte-
specific FSH was calculated as FSH per oocyte (FSHo). In order to
determine the percentage of usable embryos, the sum of embryos
transferred and cryopreserved was divided by total oocytes
retrieved. Results were multiplied by 100 to establish percentages.
Statistical Methods
A series of logistic regression was then performed to determine
whether AMHo, FSHo and the percentage of useable embryos per
oocyte yield predict clinical pregnancy in high responder patients.
Statistical analysis was undertaken using SPSS 18.0 (SPSS,
Chicago, IL). Baseline characteristics of patients were compared
using t-tests. Outcome parameters are presented as proportions.
The equation to predict the probability of clinical pregnancy per
patient based on FSHo and AMHo, derived via logistic regression,
is reported as Logit P. A P-value,0.05 was considered statistically
significant. Continuous values are presented as mean 6SD.
Results
Table 1 summarizes patient and cycle characteristics. The mean
age for all 396 women was 38.065.0 years; mean baseline FSH
was 11.868.7 mIU/mL and AMH was 1.662.1 ng/mL. Infertil-
ity diagnoses were: male factor infertility in 29.5%, tubal infertility
in 23.9%, PCOS in 18.2% and diminished ovarian reserve in
45.5% (some patients carried more than one primary diagnosis).
Out of 396 women, 88 patients qualified as high responders.
They showed mean FSH of 9.766.5 mIU/mL and mean AMH of
3.163.1 ng/mL; 8.166.4 average oocytes were retrieved in the
whole cohort, with high responders producing 15.867.1 oocytes.
Indications for fertility treatment had no significant impact on
pregnancy in high responders. However, when differences in
FSH and AMH per Oocyte Predicts Pregnancy in IVF
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were evaluated, there were statistically significant differences in the
median FSHo and AMHo values among high responders with and
without PCOS (p=0.017 and p=0.019, respectively) and with
and without diminished ovarian reserve (p=0.001 and p=0.004,
respectively). There was also a statistically significant difference
observed in FSHo between patients with and without tubal factor
(p=0.003).
A total of 103 clinical pregnancies were established, a clinical
pregnancy rate of 8.2% in poor responders, of 28.5% in normal
responders and of 34.1% in women with high age-specific oocyte
yields. The relationship between ovarian response and clinical
pregnancy was statistically significant (x
2 (2, n=396)=15.76,
p,0.001). Univariate regression analysis revealed a statistically
significant association between FSHo and pregnancy chance in
high responders (ß21.82; SE60.75; p=0.02; Logit
P=0.5092(1.816 * FSHo)) (Figure 1a). Total FSH, however,
failed to demonstrate such an association.
When the effect of FSHo was adjusted for estradiol levels at
ovulation induction, FSHo’s effect on pregnancy remained
significant (b=20.116, SE60.057, p=0.042). We then evaluated
the effect of FSHo on pregnancy, adjusting for diminished ovarian
reserve, PCOS and tubal factor in separate logistic regression
models (i.e., one model for each diagnosis). FSHo’s effect on
pregnancy also remained significant after adjusting for infertility
diagnoses (p=0.014, p=0.026, and p=0.013, respectively). When
the effect of FSHo on pregnancy potential was adjusted for age,
percentage of usable embryos and number of embryos transferred,
FSHo’s association with pregnancy also remained significant
(ß21.81; SE60.84; p=0.03). In this model, the rate of useable
embryos per oocyte yield also had, independent of FSHo, a
significant effect on clinical pregnancy outcome (ß 0.03; SE60.01;
p=0.01).
AMHo behaved similarily to FSHo. In univariate regression,
AMHo was also significantly associated with clinical pregnancy
rates in high responders (ß20.12; SE60.06; p=.03; Logit
P=0.3102(0.123 * AMHo)), while total AMH failed to show
such association (Figure 1b). We then performed a series of logistic
regressions to control for potential confounders: The effect of
AMHo remained significant when adjusted for estradiol levels at
ovulation induction (b=21.768, SE60.783, p=0.024). We then
evaluated the effect of AMHo on pregnancy, adjusting for
diminished ovarian reserve and PCOS in two separate logistic
regression models (i.e., one model for each diagnosis). AMHo’s
effect on pregnancy also remained significant after adjusting for
infertility diagnoses (p=0.026 and p=0.043, respectively). The
significant effect of AMHo on pregnancy potential in high
responders also remained significant when adjusted for usable
embryos and number of embryos transferred (ß20.12; SE60.06;
p=0.04). When adjusting for age, usable embryos per oocyte yield
and embryos transferred, usable embryos significantly predicted
pregnancy chance in high responders (ß 0.03; SE60.01; p=0.01),
while AMHo failed to reach significance (p=0.10).
Discussion
We recently reported the first use of FSHo and AMHo in
infertile women, with a majority afflicted by diminished ovarian
reserve [19]. In that cohort of women with limited amounts of
embryos for transfer, FSHo, but not AMHo, was statistically
associated with pregnancy chances. Here, in high responders,
both, FSHo and AMHo, are predictive of pregnancy chances,
while total FSH and AMH failed to demonstrate such associations.
To correctly interpret these findings, AMH’s and FSH’s varying
potentials in predicting oocyte quantity and quality should be
considered: Because of its inhibitory effect on follicle recruitment,
AMH levels rise in clinical situations associated with active
recruitment, like polycystic ovary syndrome [23], and are low
when recruitment is inactive, like in pregnancy [24], with use of
oral contraceptives [25] or in women with diminished ovarian
reserve [26,27]. If one keeps in mind that AMH is produced within
each follicle, and only during times of early follicle maturation, it
should not surprise that AMH levels rather correspond to egg
numbers than to egg quality [28], as demonstrated by our data
Table 1. Patient characteristics and cycle parameters in 396 women according to their response to controlled ovarian
hyperstimulation.
high responders normal responders low responders
(n=88) (n=235) (n=73)
Female age (years) 37.9a64.6 37.2a65.2 41.0b63.5
AMH (ng/mL) 3.1a63.1 1.4b61.5 0.4c60.5
Baseline FSH (mIU/mL) 9.7a66.5 11.1a67.7 16.5b612.1
BMI (kg/m
2) 25.6a65.8 24.5ab65.0 23.5b64.3
FSH dosage (IU/ml) 4539a62534 5689b62462 7291c62081
No. oocytes retrieved 15.8a67.1 7.2b63.6 1.5c60.5
No. embryos transferred 2.9a60.8 2.5b60.9 1.3c60.4
No. embryos cryopreserved 4.7a64.9 1.3b62.3 0.0c60.0
Percentage of usable embryos per oocyte yield (%) 50.4%a 52.4%a 86.3%b
AMHo* 11.1a621.8 11.7a616.0 10.7a623.3
FSHo** 0.9a61.3 2.1b62.1 12.2c611.0
Clinical pregnancy (%) 34.1% 28.5% 8.2%
Values are presented as means 6SD.
Means in a row that do not shoare subscripts differ at p,0.05 in the Bonferroni comparison.
*oocytes per AMH; ** FSH per oocyte.
doi:10.1371/journal.pone.0034290.t001
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pregnancy.
AMHo, in contrast, showed a significant association with
clinical pregnancy rates in high responders (p=0.03), in women
with sufficient embryos for transfer. This association remained
significant when adjusted for various impacts of excessive oocyte
yield: peak estradiol levels (p=0.04), number of embryos
transferred and usable embryos (p=0.04). AMHo, thus, appears
to demonstrate predictive ability for pregnancy and, therefore,
oocyte quality, once oocyte numbers no longer matter, while
AMHo failed to do so in a previous cohort of women with
diminished ovarian function [19]. Under such ideal circumstances,
differences in pregnancy potential might reflect granulosa cell
function. These assumptions are supported by our data that
demonstrated a significant impact of different indications for
fertility treatments (i.e., PCOS and DOR) on AMHo levels and
may shed further light on the impact of oocyte quality on
pregnancy potential in women with PCOS: Among our group of
high responders, women with higher amounts of AMH per oocyte
(i.e. lower AMHo) were more likely to achieve pregnancy. This,
however, implicates that among high responders with comparable
AMH levels, women with excessive oocyte yields experience lower
pregnancy chances. Since we controlled for the number of
embryos transferred and analysed only first cycles, our findings
suggest that, among high responders, patients with excessive
oocyte yields are more likely to have embryos with impaired
implantation potential than their high responder counterparts.
AMHo amongst high responders, thus, potentially defines two new
PCO sub-phenotypes, one with high oocyte yields and better
pregnancy chances and the other with excessive oocyte yields and
poorer pregnancy chances in association with IVF.
FSH, even longer than AMH, has been utilized to assess ovarian
reserve and predict pregnancy chances [29]. FSH, however,
reflects distinctively different stages of follicle maturation [30].
Figure 1. FSHo and AMHo and pregnancy potential in high responder patients.
doi:10.1371/journal.pone.0034290.g001
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follicular development, recent animal data suggest that FSH affects
practically all stages of follicle maturation [30], though its
significance becomes most pronounced during the last stages, the
so-called gonadotropin-sensitive phase of folliculogenesis [31]. At
such late stages it is quality, and no longer quantity of the follicle
pool that is being determined, and oocyte competence becomes
the primary issue. The expectation, therefore, would be that, in
contrast to AMH, FSH is, overall, more reflective of quality than
quantity.
Here reported FSH findings in high responders, and previously
reported data in women with diminished ovarian reserve [19],
support this hypothesis: While AMHo lost predictive capacity
when adjusted for female age, FSHo maintains predictive value for
pregnancy. These data suggest that, especially in older women,
FSHo may be the better diagnostic parameter in predicting
pregnancy chances and confirm previous findings on age-specific
discrepancies in total AMH and FSH, where FSH achieved better
predictive value above age 42 years [32].
Comparable to AMHo, FSHo, of course, also can be viewed as
defining a low and high ovarian phenotype, as, for example, the
same total elevated FSH level will result in lower FSHo with
higher oocyte numbers, and higher FSHo with fewer oocytes.
Since FSHo maintains a negative association with pregnancy
chances, the lower FSHo ovarian phenotype would denote better,
and the higher FSHo poorer pregnancy odds, as our results show.
One, therefore, can hypothesize the existence of four distinct
ovarian phenoptypes, based on AMHo and FSHo: (i) high
AMHo/high FSHo; (ii) high AMHo/low FSHo; (iii) low
AMHo/highFSHo and (iv) low AMHo/lowFSHo. Studies are
currently underway to determine whether these ovarian pheno-
types correspond with specific patient characteristics seen amongst
women with PCOS of different etiologies.
Even though FSHo remained significant after adjusting for
potential confounding factors, the rate of useable embryos also
demonstrated a significant association with clinical pregnancy,
which was independent of FSHo. This may contribute to widely
contradictory pregnancy chances reported in high responders.
While some authors describe excellent pregnancy potential even
after overt clinical ovarian hyperstimulation [33], others report
poor pregnancy rates [34,35].
AMHo and FSHo may, therefore, be used to give high
responders a better assumption of their pregnancy chances for
their current cycle. Follow up studies are required to assess a likely
effect of AMHo and FSHo on pregnancy in cryopreservation
cycles and for future IVF attempts. In addition to FSHo’s and
AMHo’s clinical impact for patient counseling, it suggests a
significant relation of granulosa cell function and pregnancy
potential in high responder patients. This may be particularly
important for different sub-types of PCOS.
Limitations and Future Research
The here presented data did not aim to identify different PCOS
subtypes. However, our results strongly support the assumption of
such phenotypes. Further studies should, therefore, address this
question.
In conclusion, here reported results demonstrate in high
responder patients a limited, likely age-restricted, predictive
significance of AMHo, and age-unlimited predictive value for
pregnancy in association with IVF for FSHo, while total AMH
and FSH levels fail to show such associations. FSHo, therefore, is
confirmed as an, overall, superior prognostic pregnancy parameter
over AMHo, as previously also reported in women with
diminished ovarian reserve. AMHo and FSHo might, therefore,
further enhance our understanding of the components of FOR
AMH and FSH best represent.
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